Home › NCT06617013

GERD in Children With Cystic Fibrosis

Characteristics of Gastroesophageal Reflux in Children With Cystic Fibrosis

Who can join

Ages 2 to 18 · All sexes

Inclusion Criteria:

* Children 2-18 years of age with a confirmed CF diagnosis by either a positive sweat test or 2 disease causing CFTR mutations.
* Signed consent

Exclusion Criteria:

* Declining to participate in the study or sign consent
* History of severe GERD per gastroenterology diagnosis and documentation
* GSAS score \>80

About the study

The purpose of this study is to evaluate the prevalence of gastroesophageal reflux disease (GERD) symptoms in pediatric patients with cystic fibrosis using the Gastroesophageal Symptom Assessment Scale (GSAS) and the impact of stopping anti-GERD therapy on the GERD symptoms reported.

What is being tested

• Discontinuation of GERD therapy (other)

Sponsor: Duke University · Participants: 20 · Started: Oct 23, 2024

Contact the study team

• Yara Salameh, MF · Phone: 919-684-8111

Official record on ClinicalTrials.gov — NCT06617013

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.